Biotech Soars On Potential ‘Best-In-Class’ Obesity Drug – Investor’s Business Daily
Biotech Soars On Potential ‘Best-In-Class’ Obesity Drug Investor’s Business Daily Structure’s Obesity Pill Delivers Weight-Loss ‘Homerun’ in Study Bloomberg.com Structure reports promising weight loss outcomes with obesity drug, but side effect questions loom statnews.com Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill The Wall Street Journal Structure Therapeutics details positive trial data for a weight-loss pill, and […]
Structure Therapeutics surges on phase 2 data for GLP-1 pill aleniglipron
7 Ways To Naturally Boost GLP-1 Production & Improve Metabolism
GLP-1 support from the grocery store? The research gets interesting
2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
Her food cravings vanished on Mounjaro then roared back
Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a patient with severe obesity. Her obsessive thoughts about food disappeared as the medication quieted the nucleus accumbens, the brain’s reward hub.
Ozempic can reduce metabolic risks in schizophrenia patients, multicenter study finds
Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with schizophrenia spectrum disorders, according to a study published in JAMA Psychiatry.
STAT+: Structure reports promising weight loss outcomes with obesity drug, but side effect questions loom
Structure Therapeutics said Monday that its investigational GLP-1 pill led to substantial weight loss in two mid-stage trials, but patients also experienced high rates of nausea and vomiting. In the first trial, a 120-mg dose of the drug, a small molecule called aleniglipron, led patients to lose 12.1% of their weight at 36 weeks, while […]
Doctor sends Christmas dinner warning to Mounjaro and Wegovy users
More than 1.5 million Brits now take GLP-1 medications
STAT+: Early update shows Wave’s RNA drug cut visceral fat
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! With STAT reporting from ASH this year, we have some stories in the blood space. Also, a potential Dupixent competitor is in the works, and we examine the fallout from Friday’s ACIP meeting. […]
Is addiction the next frontier for GLP-1 receptor agonists?
